Articles
Executive perspectives: Bruno Strigini

Executive perspectives: Bruno Strigini

As pharmaphorum continues to speak with key senior industry figures, we catch up with Bruno Strigini, President of Europe/Canada for MSD to hear his views on pharma’s future. As the pharma industry faces a number of challenges to maintaining growth rates, particularly in Western markets, it seeks to embrace the globalised nature of…

Articles
Rare disease tweet chat: how can rare diseases gain more media attention?

Rare disease tweet chat: how can rare diseases gain more med...

Rebecca Aris shares the outcomes of the rare disease tweet chat held recently by pharmaphorum. On Friday 1st February this year, pharmaphorum hosted a tweet chat on the topic of rare diseases. Many rare disease patients came together through this social...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D